TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06427746

Intervention type: PROCEDURE
Intervention: Video call
Description: Among the tools already available to improve evaluation of patients rescued in the field, SOREU has video calls between the dispatch room physician and the rescuer in the field. Thus, the rescuer in the field will perform the CPSS during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room, potentially increasing the ability to identify a stroke.

Intervention type: PROCEDURE
Intervention: Video call + LARIO
Description: LARIO scale's effectiveness in identifying patients with ischemic stroke caused by a large vessel occlusion in the anterior cerebral circulation. The anterior cerebral circulation supplies blood to the front and upper parts of the brain. Occlusion of a large vessel in this area can lead to a severe stroke. Rescuer in the field will perform the CPSS and the LARIO during ongoing video call with the dispatch room, allowing the remote evaluation of the patient by the healthcare worker present in the control room.
Study: NCT05375357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of L-PRF on the donor area
Description: After implant uncovering procedure with apically positioned flap, the donor area is covered with a layer of L-PRF

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Secondary intention healing of the donor area
Description: After implant uncovering procedure with apically positioned flap, the donor area is left to heal by secondary intention
Study: NCT04710654

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue manipulation
Description: Individuals in CTM group, will sit on a stool with hips and knees flexed at 90° and their hands free on the thighs. The application will start from the basic area in the first session, and in the other sessions, the lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment as soon as possible according to the state of the vascular reaction. CTM will be applied three days a week, for four weeks.
Study: NCT05377398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-intervention for substance use
Description: The mini-intervention for substance use follows the principle of the ASSIST-linked brief intervention created by WHO. This brief intervention is a phone-call lasting 3 to 15 minutes and given to the participant according to their risk score calculated with the ASSIST questionnaire which is included in the baseline survey. The intervention includes presenting the participant with their test score and associated health problems related to their level of risk. Especially in primary health care context, brief intervention according to the ASSIST score has been found to be successful in moderating risk for substance use. The intervention is not intended as a stand-alone treatment and in cases where high risk substance use is detected, the professional should encourage the participant to seek specialized drug and alcohol assessment and treatment.
Study: NCT06138678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS (intermittent theta-burst stimulation)
Description: The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTBS (intermittent theta-burst stimulation)
Description: The iTBS treatment is a type of rTMS (repetitive transcranial magnetic stimulation), delivered with MagPro R30 stimulator and a conventional cool-B65 coil.~The iTBS treatment is applied to over the dorsolateral prefrontal cortex using a standardized measuring of the anatomical landmark F3 from the 10-20 positioning system. The coil is positioned with the handle at in a 45 degree angle from the midline. The centre of the butterfly is placed towards the patient head.
Study: NCT05006170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT 20 mg
Description: Give 2 tabs of MYLTEGA DT (10mg) PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT 20 mg
Description: Give 2 tabs of MYLTEGA DT (10mg) PO once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG DT 25 mg
Description: Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
Study: NCT05419648

Intervention type: BIOLOGICAL
Intervention: 1 additional tube of blood
Description: For all the patients included, a specific blood sampling will be performed in addition to the classical evaluations that are performed in routine practice
Study: NCT06082180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic central neck dissection
Description: prophylactic central neck dissection was performed for the ipsilateral lesion
Study: NCT06442137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chazhu Xiaozhi decoction
Description: Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control placebo
Description: The control placebo is a ten-fold dilution of the Chazhu Xiaozhi decoction, supplemented with colorants and bittering agents to mimic the appearance and color of the treatment drug.
Study: NCT06025955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: minimally invasive non- surgical therapy
Description: hand and ultrasonic instrumentation will be done

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: flap surgery will be done
Study: NCT04444154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group with active participation
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with a demonstration of brushing methods in the sink with active participation (use of plate developer and then the Oral B electric toothbrush with special orthodontic head) during the bonding appointment as well than at each check-up appointment.
Study: NCT05144854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Specified dose on specified days
Study: NCT04444154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group with video and quizz
Description: oral hygiene advice given orally in the chair during the bonding appointment and at each check-up appointment with have an additional appointment between the device bonding appointment and the first check-up. This is a 15-minute session dedicated to teaching oral hygiene. This session will include watching of an educational video followed by a quiz, as well as the application of the methods taught in the sink (using plate developer and the Oral B electric toothbrush with special orthodontic head).
Study: NCT06536283

Intervention type: OTHER
Intervention: 13-item Barriers Questionnaire (BQ-13)
Description: Given by questionnaire

Intervention type: OTHER
Intervention: Four-item Medication Adherence Questionnaire
Description: Given by questionnaire

Intervention type: OTHER
Intervention: 14-item Hospital Anxiety and Depression Scale (HADS)
Description: Given by questionnaire
Study: NCT05622981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Age-specific educational materials and monitoring
Description: Subjects will receive age-specific behavioral modification and educational materials plus every 2-week monitoring for goals and progress at reducing BMI for 24 weeks in the pediatric primary care clinic.
Study: NCT05386160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection of Ranibizumab；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection of Ranibizumab；

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification
Description: Phacoemulsification
Study: NCT04920565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hemoperfusion with polymyxin B
Description: polymyxin B is covalently immobilized on polystyrene strands, selectively removes endotoxin and at the same time there is no leaching of the ligand, immobilization is carried out by electrostatic interaction and Vanderwals force
Study: NCT05255354

Intervention type: DEVICE
Intervention: ClonoSEQ
Description: Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.

Intervention type: DEVICE
Intervention: ClonoSEQ
Description: Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.

Intervention type: DEVICE
Intervention: ClonoSEQ
Description: Cancer clonotype sequences are identified in diagnostic 'ID' samples and then sequence frequencies are measured in follow up samples.
Study: NCT06442059

Intervention type: OTHER
Intervention: Kinesiophobia Level Due to Dyspnea
Description: Kinesiophobia Level Due to Dyspnea
Study: NCT05730088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Health Education: While they are still in the hospital, a 30-minute individually planned education about their disease will be given to patients using the COPD patient education booklet. step 1. Smoking cessation, step 2. Vaccination, step 3. Correct drug use, step 4. Regular exercise, step 5. Healthy eating, step 6. Coping with stress, step 7 Coping with attacks, step 8. Includes regular oxygen therapy. Let's learn nhaverug treatments in coping with COPD, under the title of pulmonary rehabilitation (Respiratory Rehabilitation), methods of coping with shortness of breath, indoor air pollution and outdoor air pollution subheadings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application (Creating a WhatsApp group):
Description: A group will be created through the WhatsApp application for participants in health education and visual and audio materials will be shared through this group every week. In the coming weeks, the researcher will provide consultancy services to those who have problems with the application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone interview:
Description: Participants will be called every month by the researcher and asked if there are any hospital visits in that month, especially if they are chest disease visits.
Study: NCT06471231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min
Description: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min
Description: the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP
Study: NCT05144854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Specified dose on specified days
Study: NCT06141798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: Number of weekly hemodialysis treatment
Study: NCT05897593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlenXRose Augmented Reality Acquired Brian Injury Therapies
Description: Rehabilitation therapies for ABI have been developed for augmented reality implementation. These include various games to interact within an augmented environment while conducting rehabilitation therapy.
Study: NCT05854147

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treadmill Training With Visual and Auditory Cues
Description: Comparison of Effects of Treadmill Training With Visual and Auditory Cues

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Treadmill Training Without Visual and Auditory Cues
Description: Comparison of Effects of Treadmill Training Without Visual and Auditory Cues
Study: NCT04632667

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison School Group
Description: All control schools will receive training and materials for the CATCH sun safety curriculum. Ray and the Sunbeatables®: A Sun Safety Curriculum is an evidence-based curriculum educates children, parents and teachers about sun protection and promotes sun safety behaviors in an effort to reduce children's lifetime risk of developing skin cancer. Training will be conducted with booster trainings yearly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention School Group
Description: This intervention includes toothbrushing which will be implemented as a daily activity to develop skills and technique,classroom curriculum, which includes theory-based interactive lessons on oral health care,the physical education component consisting of an activity box containing different structured physical activities that will integrate the nutrition and oral health education messages, all cafeteria-based intervention materials including the tooth friendly Eat Smart guide, signage, nutrition labeling, menu planning and labeling using the tooth-friendly Go-Slow-Whoa CATCH terminology will be provided to the food service staff that is displayed across the cafeteria and sent home to parents and parents will be provided with tools and tips for maintaining oral health with website resources,parent-child homework activities, send-home infographics on dental care, parent-monitored tracking of child oral health,family fun nights in schools, and social media.
Study: NCT04563026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 30 mg
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 90 mg
Description: IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Standard of Care (SOC)
Description: IV infusion
Study: NCT05117073

Intervention type: DIAGNOSTIC_TEST
Intervention: ASCITIC FLUID CULTURE
Description: Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate

Intervention type: DIAGNOSTIC_TEST
Intervention: ASCITIC FLUID CULTURE
Description: Ten milliliters of ascitic fluid will be collected at the bedside and inoculated into aerobic and anaerobic blood culture bottles. Bacterial culture will be performed manually using MacConkey and blood agar plate
Study: NCT05498831

Intervention type: OTHER
Intervention: Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse
Description: Pain will be assessed using a numerical scale

Intervention type: OTHER
Intervention: Pain assessment at 15 minutes, 30 minutes, 60 minutes, 120 minutes after initial assessment by the triage nurse
Description: Pain will be assessed using a numerical scale
Study: NCT06568640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superselective adrenal arterial embolization
Description: Superselective adrenal arterial embolization is an operation to inject embolic agent into adrenal artery through catheter to embolize part of adrenal gland, so as to reduce the secretion of adrenal hormone and reduce blood pressure.
Study: NCT06568965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-stress & happy gut powder-U001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: De-Stress & Happy Gut powder-I001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Powder 001
Description: Take one sachet daily, 30 minutes before breakfast, for 60 days
Study: NCT05652816

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Split-thickness skin graft
Description: Transplantation of autologous skin to burn area

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artificial skin graft
Description: Decellularized amnion membrane formed into 3-D matrix

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Artificial skin graft co-culture
Description: Decellularized amnion membrane formed into 3-D matrix seeded with autologous keratinocyte co-cultured with amnion epithelial stem cells
Study: NCT06540326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome (II)
Description: irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan liposome (II)
Description: irinotecan liposome (II) is a powerful chemotherapeutic agents, in the combination with fluorouracil，and bevacizumab or cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: fluorouracil is a powerful chemotherapeutic agents, in the combination with irinotecan liposome (II)，and bevacizumab or cetuximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab is a powerful targeted agents, in the combination with irinotecan liposome (II)，and fluorouracil
Study: NCT04586569

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pediatric Interactive Relational Agent (PIRA)
Description: The PIRA is an interactive, online tool used to educate children and families about their child's upcoming surgical and anesthesia experience.
Study: NCT05706454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramatroban
Description: Route of Administration: Oral Dose: 75 mg; Frequency: Twice daily; Total duration of intervention: 28 days.~Subjects will be evaluated over a study period of approximately 365 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally twice a day
Study: NCT05761015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic program including intermittent drug intake and multimodal rehabilitation program
Description: The prescribed NSAID molecule shall be chosen according to the patient's risk profile:~* gastric/duodenal risk: age \>65, history of ulcer with remission, history of inflammatory event, current low-dose acetylsalicylic acid treatment ;~* cardiovascular risk (according to Agostino scale \& SCORE);~The molecule with therefore be:~* no risk: niflumic acid, 250 mg per intake;~* gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole;~* cardiovascular risk only: ketoprofen, 50-100 mg per intake;~* double risk: ibuprofen, 200-400 mg per intake, plus lansoprazole. For the walk test, the highest dose of diclofenac or ketoprofen will be used. Then, the patient will be free to half the dose if pain relief is achieved so.~One gram of acetaminophen will be added to any NSAID intake. The number of intakes will be limited to twice a day (morning and evening) and to 10 times a week.
Study: NCT06540755

Intervention type: GENETIC
Intervention: genetic polymorphism analysis
Description: Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.

Intervention type: GENETIC
Intervention: genetic polymorphism analysis
Description: Genotype for IL-6 rs1800795 and PAPP-A rs7020782 polymorphisms were determined using real-time polymerase chain reaction with allele-specific probes.
Study: NCT05001373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Core-g28v2 60mer mRNA Vaccine
Description: 100µg, Intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Core-g28v2 60mer mRNA Vaccine
Description: 100µg, Intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Core-g28v2 60mer mRNA Vaccine
Description: 100µg, Intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer mRNA Vaccine
Description: 100µg, Intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer mRNA Vaccine
Description: 100µg, Intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer mRNA Vaccine
Description: 100µg, Intramuscularly
Study: NCT05647200

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment: additional albumin during cardiopulmonary bypass
Description: Treatment group (T): administration of 100 mL Human Albumin (20%), first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: control: additional ringers during cardiopulmonary bypass
Description: Control group (C): administration of 100 mL of Ringer's solution, first dose directly after aortic cross clamping and blood cardioplegia administration, second dose after the third blood cardioplegia administration (± 30 min after the first dose).
Study: NCT06240572

Intervention type: OTHER
Intervention: no intervention
Description: no intervention